POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop ...

SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs ...

NEWARK, CALIFORNIA / ACCESS Newswire / November 3, 2025 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") announced that clinical data on rusfertide in polycythemia vera, including the ...

COPENHAGEN, DENMARK / ACCESS Newswire / November 3, 2025 / FluoGuide A/S (STO:FLUO) ("FluoGuide" or the "Company") announces that it has issued 199,000 warrants to members of the board directors, ...

Financial Assistance From The Assistance Fund Now Available for Eligible People Living With Macular Telangiectasia ORLANDO, FL / ACCESS Newswire / November 3, 2025 / The Assistance Fund, an ...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SWITZERLAND OR ANY OTHER ...

Generation Wellness to a Global Audience with Multilingual, Accessible AI Solutions MESA, ARIZONA / ACCESS Newswire / November 3, 2025 / Medical Care Technologies, Inc. (OTC Pink:MDCE) is excited to ...

CID-103 is a potential best-in-class, anti-CD38 monoclonal antibody- Phase 1 dose escalation study in Immune Thrombocytopenia (ITP) results and update SOUTH SAN FRANCISCO, CA / ACCESS Newswire / ...

LUND, SE / ACCESS Newswire / November 3, 2025 / BioInvent International AB ("BioInvent")(STO:BINV)(Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first ...

Dr. Naderi reveals how younger generations are embracing prejuvenation with collagen-boosting treatments and skincare to maintain a natural, youthful glow before aging signs appear. RESTON, VA / ...

Voters and researchers head to Parliament to see how politicians are using evidenceThe public has made it clear that they expect MPs to look at the evidence when making decisions[1]. Following a ...

The hazard ratio (HR) for the primary endpoint was (3.84, p = 0.0009) in the first monthThe Prolocor pFCG™ test has the potential to help providers reduce 30-day readmission rates for Acute MI, ...